Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VGX-3100 for Anal HSIL in HIV-Positive Individuals
NCT03603808Phase 2Completed
- Sponsor
- AIDS Malignancy Consortium
- Start
- Sep 2018
- Primary completion
- Dec 2024
- Modality
- Prophylactic Vaccines, DNA Vaccines, Cancer Vaccines
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of bizalimogene ralaplasmid in anal squamous intraepithelial lesion (ASIL), sponsored by AIDS Malignancy Consortium. Primary endpoint: Overall Response Rate at 48 weeks. Started Sep 2018; status: completed.
02
Drugs
bizalimogene ralaplasmid
03
Conditions
anal squamous intraepithelial lesion (ASIL)
Beyond the preview
Go deeper on NCT03603808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03603808.